Clinical Scorecard: Identifying the Best OSD Treatment for Your Patient

At a Glance

Key Highlights

• DED affects 5% to 50% of individuals worldwide and significantly impacts daily activities and quality of life.
• Treatment options have expanded from artificial tears to include immunomodulators, corticosteroids, neurostimulants, and targeted therapies for Demodex blepharitis.
• A stepwise approach to management is recommended, starting with simple lubricants and escalating to advanced therapies based on patient response.

Guideline-Based Recommendations

Diagnosis

• Use validated tools like the Ocular Surface Disease Index (OSDI) to assess symptoms.
• Employ advanced diagnostics such as tear osmolarity testing and MMP-9 screening to confirm DED.

Management

• Begin with preservative-free artificial tears for symptomatic relief.
• Escalate treatment to punctal plugs, pharmacologic agents (e.g., cyclosporine, lifitegrast), amniotic membrane, autologous serum tears, or intense pulsed light therapy as needed.
• Use topical corticosteroids (loteprednol etabonate) short-term for flare-ups.
• Consider newer agents like perfluorohexyloctane to reduce tear evaporation and varenicline nasal spray for neurostimulation of tear production.
• Treat Demodex blepharitis with lotilaner ophthalmic solution.

Monitoring & Follow-up

• Monitor patient adherence and tolerability, noting common adverse events such as ocular burning, irritation, redness, and visual disturbances.
• Assess symptom relief and ocular surface health regularly to adjust therapy accordingly.

Risks

• Pharmacologic treatments may cause mild-to-moderate ocular burning, instillation-site pain, conjunctival hyperemia, and dysgeusia.
• Intranasal varenicline may cause sneezing, coughing, and throat irritation.
• Long-term corticosteroid use risks should be mitigated by limiting duration to short-term flare management.

Patient & Prescribing Data

Patients with chronic DED and ocular surface inflammation

Patients show higher continuation rates with cyclosporine ophthalmic solution 0.09% (Cequa) compared to other immunomodulators; newer formulations like Vevye offer improved comfort and rapid symptom relief.

Clinical Best Practices

• Adopt a stepwise treatment approach tailored to individual patient needs and disease severity.
• Incorporate diagnostic advancements to accurately identify and monitor DED.
• Educate patients on potential side effects and the importance of adherence to therapy.
• Prepare the ocular surface prior to cataract and refractive surgeries to optimize outcomes.
• Utilize emerging therapies to address specific pathophysiologic mechanisms such as tear evaporation and Demodex infestation.

References

• Dry Eye Disease Prevalence and Impact
• FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
• Ocular Surface Disease Index (OSDI) Development
• Tear Osmolarity and MMP-9 Testing in DED
• Impact of Ocular Surface Health on Surgical Outcomes
• Adverse Events of Cyclosporine and Lifitegrast
• Comparative Study of Restasis, Cequa, and Xiidra
• FDA Approval of Perfluorohexyloctane (Miebo)
• Clinical Experience with Vevye Cyclosporine Formulation
• Loteprednol Etabonate for DED Flare-ups
• Varenicline Nasal Spray Mechanism and Efficacy
• Lotilaner Ophthalmic Solution for Demodex Blepharitis